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 Abstract 1 
As the human papillomavirus (HPV) vaccine is now recommended for males, a reliable, comprehensive HPV 2 
knowledge measurement tool which addresses issues relevant to males is needed. We aimed to replicate, 3 
validate and test the comprehensiveness of an existing general HPV and an HPV vaccination knowledge scale 4 
in English and French. We also measured parental HPV knowledge and changes over time. An online 5 
questionnaire was administered in February (Time 1; T1) and November 2014 (Time 2; T2) to a nationally 6 
representative sample of Canadian parents of boys. Dimensionality, internal consistency and model fit were 7 
evaluated at both time points and separately in English and French sub-samples. Differences in knowledge 8 
scores were measured. Analyses were performed on 3117 participants at T1 and 1427 at T2. The 25-item HPV 9 
general knowledge and an 11-item HPV vaccination scale were uni-dimensional, showed high internal 10 
consistency (α>0.87, α>0.73) and had good model fit. Both general HPV and vaccine-specific knowledge 11 
significantly increased over time in both languages, but remained low at T2, with only about half of the items 12 
being answered correctly. Correct responses at T2 are best explained by correct responses at T1, with some 13 
small changes from ‘Don’t know’ at T1 to correct at T2.  14 
The extended general and vaccine-specific knowledge scales are valid, reliable and comprehensive, and could 15 
be used among parents of boys, in both English and French. Educational interventions could target specific 16 
knowledge gaps and focus on providing information rather than correcting misconceptions.  17 
 18 
Keywords: Human papillomavirus (HPV); Papillomavirus vaccines; Papillomavirus Infections/prevention & 19 










Strong empirical evidence supports the causal role of the human papillomavirus (HPV) in the 22 
development of cervical, vaginal, penile, anal and oropharyngeal cancers and genital warts (Forman et al., 2012; 23 
Vardas et al., 2011). In Canada, all provinces and territories vaccinate females against HPV as part of provincial 24 
school-based immunization programs i.e., grades 4 through 8 (~10-14 years old), dependent on location(Shapiro 25 
et al., 2016). Most organizations now also recommend HPV immunization for males (Centers for Disease 26 
Control and Prevention, 2015; Public Health Agency of Canada, 2015; WHO Report, 2015). In Canada, the 27 
HPV vaccine has been included for boys in school-based provincial immunization programs, with other 28 
provinces due to follow in the autumn 2016 (e.g. Alberta (autumn 2014), Prince Edward Island (PEI) (autumn 29 
2013), and Nova Scotia (autumn 2015) for grade 5, 6 and 7 (~11-13 years old), respectively. Quebec and 30 
Manitoba are set to begin programs (autumn 2016) for boys in grades 4 and 6 respectively (Public Health 31 
Agency of Canada, 2016; Shapiro et al., 2016).Across many parts of Canada, HPV vaccination uptake for girls 32 
is not reaching the  ~70% needed to provide herd protection (Brisson et al., 2011; Public Health Agency of 33 
Canada, 2014). Data from the first male HPV immunization program in PEI indicates that although HPV 34 
vaccination uptake was high (79% for males and 85% for females), grade six girls had a 1.5 higher likelihood of 35 
being vaccinated compared to boys of the same age (McClure et al., 2015). In this early period where male HPV 36 
vaccination programs are being initiated, there is a need to understand what influences parental decision-making 37 
concerning HPV vaccination for their sons. 38 
Psychosocial research examining the factors that influence HPV vaccination acceptance suggests a 39 
direct relationship exists between parents’ HPV and HPV vaccine knowledge and intentions to vaccinate against 40 
HPV (Allen et al., 2010; Giambi et al., 2014; Pelucchi et al., 2010). A comprehensive measurement of parents’ 41 
HPV knowledge is important to target HPV vaccine specific knowledge gaps, web designing and implementing 42 
educational interventions, aimed at increasing HPV vaccine uptake. A reliable HPV general knowledge and 43 
HPV vaccination specific knowledge scale was developed and validated by Waller and colleagues (2013). 44 
While the scales were extensively psychometrically tested and found to be structurally cohesive and reliable, 45 
they do not capture knowledge items relevant to males (e.g., did not assess knowledge about HPV-associated 46 
diseases beyond cervical cancer) and were only validated among English speakers. Waller et al. concluded with 47 
the recommendation to validate the measure in other settings and languages and to examine the addition of new 48 
items particularly when the HPV vaccine becomes readily available for males.  49 
The present study’s objectives were 1) to replicate the validation of the general HPV and HPV vaccine 50 
knowledge scales proposed by Waller and colleagues among a national sample of both English and French-51 
speaking Canadian parents of boys; 2) to examine whether our additional items add to the comprehensiveness 52 
and cohesiveness of the existing general HPV knowledge and HPV vaccine scales and; 3) to measure and 53 
describe general HPV and HPV vaccine knowledge patterns of change over time. 54 
Methods 55 
Study Participants and Design  56 
Parents who had a son aged 9-16 years old living in their household were recruited through a research 57 
firm, Leger Marketing, which maintains a representative panel of 400,000 Canadian households. We targeted a 58 
sample of 4,000 parents, weighted according to the population distribution of the ten Canadian provinces. In 59 
February 2014, panel participants who met the inclusion criteria were sent an invitation email with a link to the 60 
online study. Participants elected whether they preferred to answer the questionnaire in English or French.  61 
Data were collected using an online questionnaire that took approximately 20 minutes to complete and 62 
contained a variety of quantitative and qualitative items including: socio-demographics, knowledge, HPV 63 
vaccination attitudes, and health behaviors. The focus of this study is on the HPV and HPV vaccine knowledge 64 
items. Participants who completed the questionnaire at Time 1 (T1) and deemed eligible respondents were 65 
invited to re-complete the questionnaire at 9-months follow up (November 2014, Time 2, (T2)). The study was 66 
approved by the Research Ethics Board at the Jewish General Hospital, Montreal, Canada. A detailed 67 
methodology of the study protocol and sample characteristics is provided elsewhere (Perez, S. et al., 68 
Determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological 69 
challenges and initial results of a pan-Canadian longitudinal study, under review). 70 
Knowledge Items  71 
The authors expanded upon the HPV-general knowledge (herein referred to as GK) and the HPV-72 
vaccine knowledge (herein referred to as VK) scales published by Waller et al (2013), who, using a Principal 73 
Axis Factor Analysis (PFA), found that both a 16-item HPV knowledge subscale, GK (α=0.849) and the 7-item 74 
HPV vaccination knowledge subscale, VK (α= 0.561) were reliable and uni-dimensional (2013). Results of the 75 
Confirmatory Factor Analysis (CFA) suggested a better fit for the 16-item GK scale than for the 7-item VK 76 
scale. 77 
 The present study included the identical Waller et al.’s 16-item GK scale with two minor semantic 78 
changes (shown in italics): “HPV can be transmitted through general skin-to-skin contact” and “Using condoms 79 
reduces the chances of HPV transmission1.” Our study also included the identical Waller et al.’s 7-item VK 80 
scale with one semantic change: “Girls who have had the HPV vaccine do not need a Pap test (cervical cancer 81 
screening) when they are older2”. It was also necessary to slightly revise one of the VK items about dosing as 82 
since Waller et al.’s (2013) publication, the WHO recommendation(WHO Report, 2015) had shifted from a 83 
                                                          
1Waller’s items: HPV can be passed on during sexual intercourse; Using condoms reduces the risk of getting HPV 
2Waller’s items: Girls who have had the HPV vaccine do not need a [Pap test/Smear test/Pap smear test] when 
they are older 
three to a two-dose policy for children under 15 years of age (“The HPV vaccine requires only one dose3”). 84 
Response options were identical to Waller’s scale and used forced choice response categories of 85 
True/False/Don’t know. 86 
Based on our previous HPV research (Krawczyk et al., 2015; Krawczyk et al., 2013; Krawczyk et al., 87 
2012), consultation with an expert panel and a comprehensive literature search, we identified additional 88 
knowledge items that were not included in Waller’s scale. These items reflected the most up-to-date emerging 89 
scientific evidence and were frequently being measured in the HPV psychosocial/epidemiological literature 90 
(Daley et al., 2009; Daley et al., 2010; Fisher, Personal communication; Gerend and Barley, 2009; Giede et al., 91 
2010; Gutierrez et al., 2013; Katz et al., 2011). The addition of the 9 GK (see Appendices A & B; items 17- 25 92 
for the new added items) and 4 VK items (see Appendices A & B; items 8- 11 for the new added items) aimed 93 
to measure: 1) the association of HPV with oral, penile, and anal cancers (items 17, 20, 24), 2) transmission 94 
(items 19, 22, 25), 3) HPV-associated signs and symptoms (items 18, 21, 23), 4) prevention (items 8), 5) 95 
treatment (item 9), 6) the recommendation for males and females in the Canadian context (items 10,11) (see 96 
Appendices A & B). 97 
Questionnaire development took into account language and literacy levels. The entire questionnaire was 98 
pilot tested for readability and validity with 20 parents of 9-16-year-old boys. The reading level of the survey 99 
was measured using the Flesch-Kincaid scale available through Microsoft Word (Microsoft Corp., Redmond, 100 
WA) and found to be appropriate for a grade 8 reading level. The English survey was translated into French by 101 
a specialized translation firm with expertise in health literacy and reviewed for accuracy by an independent 102 
bilingual group of professionals (n=5) working in the healthcare field. Questionnaire development and 103 
translation was reviewed by a bilingual panel of seven highly experienced HPV researchers. 104 
GK and VK scores were calculated by assigning 1 point to each correct answer and zero points for 105 
incorrect or ‘Don’t know’ answers (Range= 0-25 for GK and range=0-11 for VK). A GK and VK total score 106 
were calculated at baseline (Time 1, T1) and at 9-months follow up (Time 2, T2) for the English and French 107 
sub-samples.  108 
Analysis 109 
Analyses were performed on the T1 and T2 samples separately, which were also divided into two sub-110 
samples, English and French respondents. Analyses included internal consistency analysis (Cronbach’s alpha), 111 
exploratory factor analysis (EFA) to investigate dimensionality and a CFA to investigate validity (model fit). 112 
Results for the 16-item GK scale and the 7-item VK scale in French and English were compared with the results 113 
obtained by Waller et al. (2013). The effects of adding nine  new GK items and four new VK items on internal 114 
consistency and dimensionality were then investigated by comparing the scale properties with and without the 115 
                                                          
3Waller’s item: HPV vaccines require three doses 
additional items. Additionally, descriptive statistics and Welch two sample t-tests, p <0.05 were used to explore 116 
knowledge scores over time and across languages. 117 
For the EFA, a PFA was used with varimax rotation. Similar to Waller’s analysis, four criteria (Slocum-118 
Gori and Zumbo, 2010) were used to explore dimensionality; three criteria are presented in Table 2. Results for 119 
the fourth criterion, examining items that did not load higher than 0.33 on a forced one-factor solution, are 120 
presented in text. For the CFA, results are based on four indices (Hu and Bentler, 1999) (see Table 3 and Table 121 
4). Differences in proportions were tested using Chi-square, p<0.05. Statistical analysis was conducted using 122 
SPSS v21, Stata 13 and R Studio v0.99.896. 123 
Results 124 
At T1 n=3117 respondents and at T2, n= 1427 respondents were included in the analysis. At T1, 2117 125 
participants from T1 completed the questionnaire in English and 1000 in French. At T2, 873 participants 126 
completed the questionnaire in English and 554 completed it in French.  127 
Internal Consistency Analysis 128 
The internal consistency results for the GK16 compared favorably with the results obtained by Waller et 129 
al. The internal consistency of the GK25 was higher than GK16 across all subsamples (Table 1). Item level 130 
analysis indicated that the item “HPV usually doesn’t need any treatment” sometimes had a slightly negative 131 
effect (in the third decimal place) on scales’ internal consistency.  132 
Internal consistency values for the VK7 and VK11 subscales were higher than those found by Waller et 133 
al. (Table 1). Item specific analysis suggested a slight misfit for the item “One of the HPV vaccines offers 134 
protection against genital warts” but the effect was very small. 135 
  136 
Table 1 Internal Consistency (Cronbach’s alpha) of HPV General Knowledge (GK) and HPV Vaccine 137 
Knowledge (VK) across subsamples at Time 1 (T1) and Time 2 (T2). 138 
 139 
 140 
 HPV general knowledge (GK) HPV Vaccine Knowledge (VK) 
GK16 GK25 VK7 VK11 
T1 
French 
(n = 1000) 
0.869 0.902 0.699 0.778 
English 
(n = 2117) 
0.898 0.922 0.733 0.819 
Combined 
(n = 3117) 
0.889 0.916 0.722 0.807 
T2 
French  
(n = 554) 
0.828 0.874 0.651 0.737 
English  
(n = 873) 
0.855 0.894 0.619 0.742 
Combined 
(n = 1427) 
0.844 0.887 0.629 0.739 
    Note. Waller et al. GK (16 items) α = 0.849; Waller et al. VK (7 items) α = 0.561 141 
 142 
Dimensionality Analysis (EFA) 143 
 For the GK16, on all subsamples and at both time points, we obtained only one factor with Eigenvalue 144 
(EV) >1; the extracted loading of factor one was more than three times larger than factor two (F1>3xF2); and 145 
the one factor percentage of common variance (1FVar) was higher than the reference value (27.78) from 146 
Wallers’ scale (2013), with one exception. Item level analysis found that the item “HPV usually doesn't need 147 
any treatment” failed to load greater than .33 on a 1-factor solution for all subsamples and at both time points. 148 
 For the GK25, the criteria F1 > 3xF2 and 1FVar were met (Table 2) for all subsamples and at both time 149 
points. At T1 and T2, the percentage of common variance accounted for in the French language sample was 150 
lower than that of the English sample (Table 2). A consistent finding, with the exception of the T1 combined 151 
sample, was that the addition of the nine new items (GK25) resulted in three factors with EV greater than 1 152 
(Table 2). Similar to the GK16, the item “HPV usually doesn't need any treatment” failed to load greater than 153 
.33 on a 1-factor solution. The item “HPV can cause herpes” also failed to load greater than .33 on a 1-factor 154 
solution for the French language at the second time point. 155 
EFA results for VK7 and VK11 across both language subsamples and at both time points found only one 156 
factor with an EV > 1 (Table 2). In almost all cases, F1 was > 3xF2 (Table 2). For both the VK7 and the VK11 157 
and across all subsamples, the percentage of variance accounted for by a 1-factor solution was higher (22.17-158 
31.39) than the percentage of variance obtained by Waller et al. (21.65). Item level analysis indicated that for 159 
both the VK7 and the VK11, most items loaded >0.33 on the one factor solution for all subsamples at both time 160 
points. The item “One of the HPV vaccines offers protection against genital warts” frequently failed to load 161 
>0.33 and the items “The HPV vaccines offer protection against most cervical cancers” and “The HPV vaccine 162 
only requires one dose” occasionally failed to load >0.33. 163 
 Table 2. Results of the Exploratory Factor Analysis on all subsamples 
 GK16 GK25 VK7 VK11 




One Yes 31.35 Three Yes 27.9 One Yes 26.61 One Yes 26.32 
English 
(n = 2117) 
One Yes 37.18 Three Yes 33.09 One Yes 31.39 One Yes 31.12 
Combined 
(n = 3117) 
One Yes 35.26 Two Yes 31.32 One Yes 30.38 One Yes 29.48 
T2 
French  
(n = 554) 
One Yes 26.03 Three Yes 23.26 One No* 25.26 One Yes 22.85 
English  
(n = 873) 
One Yes 29.72 Three Yes 27.04 One No* - One Yes 22.28 
Combined 
(n = 1427) 
One Yes 28.13 Three Yes 25.38 One No* - One Yes 22.17 
 
Note. EV= Eigenvalue; EV>1= number of factors with EV>1; F1>3xF2=extracted loadings of factor1 three times bigger than factor 2; 1FVar= 1 factor % common variance;  
* =very close to yes. Waller’s results for the 16-item GK scale were: EV>1=one; F1>3xF2=Yes; 1FVar=27.78. Waller’s results for the 7-item VK scale were: EV>1=1; 
F1>3xF2=No; 1FVar=21.65. 
Model fit (CFA) 185 
 CFA analysis for the GK16 and the GK25 found that the Standardized Root Mean Square Residual 186 
(SRMR) and the Coefficient of Determination (CD) values met the suggested model fit criteria (Hu and Bentler, 187 
1999). The Comparative Fit Index (CFI) values were close to the cutoff criteria while the p value for Chi square 188 
and Root Mean Square Error Approximation (RMSEA) criteria for model fit were not met (Table 3). For the 189 
VK7 and the VK11, previous observations related to cut-off criteria for the GK scales apply (Table 4).  190 
Table 3. Results of the Confirmatory Factor Analysis for the 16 and 25-item HPV General Knowledge (GK) 191 
scales  192 
 GK16 GK25 






.843 .087 .055 .900 2571.48 
p<.001 





.905 .074 .042 .918 4807.88 
p<.001 
.784 .088 .066 .933 
Combined 
(n = 3117) 
2054.54 
p<.001 
.889 .078 .045 .912 7185.70 
p<.001 






.853 .081 .055 .895 1435.47 
p<.001 





.904 .073 .045 .916 2308.79 
p<.001 
.766 .092 .070 .931 
Combined 
(n = 1427) 
948.23 
p<.001 
.889 .075 .047 .908 3518.88 
p<.001 
.749 .091 .071 .923 
 
Note. χ2=Chi square; CFI= comparative fit index; RMSEA= root mean square error approximation;  193 
SRMR= standardized root mean square residual; CD= coefficient of determination.  194 
Cut-off criteria: a) p for χ2> 0.05, b) CFI > 0.9, c) RMSEA<0.06, d) SRMR<0.08 and e) CD as close as possible to 1. Waller et. al 195 
results: Chi square 1981.6, p<0.0001; CFI=.816; RMSEA=.087; SRMR=.063; NFI=.809  196 
Table 4. Results of the Confirmatory Factor Analysis for the 7 and 11-item HPV Vaccination Knowledge (VK) 197 
scales  198 
 VK7 VK11 






.908 .090 .052 .804 294.02 
p<.001 





.930 .085 .049 .822 576.73 
p<.001 
.909 .076 .048 .863 
Combined 
(n = 3117) 
335.48 
p<.001 
.925 .086 .049 .815 834.75 
p<.001 






.899 .084 .052 .767 174.02 
p<.001 





.917 .086 .053 .799 275.40 
p<.001 
.896 .078 .051 .850 
Combined 
(n = 1427) 
154.44 
p<.001 
.914 .084 .051 .786 409.95 
p<.001 
.886 .076 .050 .833 
 
Note. χ2=Chi square; CFI= comparative fit index; RMSEA= root mean square error approximation;  199 
SRMR= standardized root mean square residual; CD= coefficient of determination.  200 
Cut-off criteria: a) p for χ2> 0.05, b) CFI > 0.9, c) RMSEA<0.06, d) SRMR<0.08 and e) CD as close as possible to 1. Waller et. al 201 
results: Chi square 428.9, p<0.0001; CFI=.793; RMSEA=.111; SRMR=.083; NFI=.789  202 
GK across Time and Language 203 
Consistently, for every single item for both the English and French subsamples, there was an increase in 204 
the proportion of correct responses from T1 (n=3117) to T2 (n=1427). This increase was significant for 24 from 205 
25 items for the English sample and 21 from 25 items for the French sample. For example, two items with the 206 
largest significant increase (12-25%) over time in both English and French were “Men cannot get HPV” and 207 
“HPV can cause cancer of the penis”. Importantly, the overall mean GK25 score significantly increased for both 208 
languages across time (MeanEN at T1=11.76; MeanEN at T2=14.23, t=9.78, CI [1.97; 2.95] and MeanFR at 209 
T1=11.47; MeanFR at T2=13.69, t=7.35, CI [1.63; 2.82]).   210 
There were differences in the proportion of correct answers at the item level between English and 211 
French samples at both time points i.e., 18 from 25 items significantly differed between French and English 212 
samples at T1 and 15 from 25 significantly differed between French and English samples at T2. Importantly, 213 
there was no significant difference between the overall mean GK25 score for the two languages at either time 214 
point (MeanEN=11.76 and MeanFR= 11.47 at T1) and (MeanEN= 14.23 and MeanFR=13.69 at T2).  215 
VK across Time and Language 216 
An identical pattern as GK25 was found for VK11. There was an increase in the proportion of correct 217 
responses for every single item for both the English and French subsamples from T1 (n=3117) to T2 (n=1427). 218 
This increase was significant for 11 of 11 items for the English sample and 9 of 11 items for the French sample. 219 
For example, two items with the largest significant increase (11-27%) over time were “The HPV vaccine is 220 
approved and recommended by Health Canada for males aged 9-26 years” and “Someone who has had the HPV 221 
vaccine cannot develop cervical cancer”. Importantly, the mean VK11 score significantly increased for both 222 
languages across time (MeanEN at T1=5.21; MeanEN at T2= 6.38, t=10.4, CI [0.94;1.39] and MeanFR at T1 =5.26 223 
and MeanFR at T2 =6.17, t=6.52, CI [0.63;1.18]). 224 
There were differences in the proportion of correct answers at the item level between English and 225 
French samples at both time points i.e., 7 of 11 items significantly differed between French and English at T1 226 
and 4 of 11 significantly differed between FR and EN at T2. Importantly, there was no significant difference 227 
between the overall mean VK11 score for the two languages at either time point (MeanEN=5.21 and MeanFR= 228 
5.26 at T1) and (MeanEN=6.38 and MeanFR=6.17 at T2).  229 
Knowledge Patterns of Change 230 
An examination of knowledge changes over time was conducted among those participants who 231 
answered the questionnaire at both T1 and T2 (n=1427). At T1, for the GK25, participants answered 49.1% of 232 
items correctly, 13.2% of items incorrectly and 37.7% of answers as “Don’t know”. At T2, at the item level, 233 
less than 50% of the sample achieved the correct answers for 10 out of 25 GK items (Figure 1). The mean 234 
knowledge score for the GK25 scale at T1 was 12.28/25 and 14.02/25 at T2, (t=7.56, 95% CI [1.29; 2.19] 235 
p<0.001).  236 
At T1 for the VK11, participants answered 49.9% of items correctly, 9.6% of items incorrectly and 237 
40.5% of answers as “Don’t know”.  At T2, at the item level, less than 50% of the sample got the correct answer 238 
for 5 out of the 11 VK items (Figure 2). The mean knowledge score for the VK11 scale at T1 was 5.49 of 11 239 
and 6.3 of 11 at T2, (t=7.86, 95% CI [0.6; 1.0], p<0.001). The most and least known GK items at T2 are 240 
provided in Figure 1 and the most and least known VK items at T2 are provided in Figure 2.  241 
Item-level analysis of both the GK and VK scales revealed that for best known items, correct responses 242 
at T2 can be best explained by correct responses at T1 (Figure 1 and Figure 2). For both GK and VK items, few 243 
correct responses at T2 can be explained by changing from incorrect at T1Figure 1Figure 2.  The number of 244 
correct responses at T2 originating from “Don’t know” answers at T1 was relatively constant across items 245 
(Figure 1). For GK, the largest increase was observed for parents who did not know at T1 that: a) men can get 246 
HPV, b) HPV can cause cancer of penis and c) HPV can be transmitted through anal sex (Figure 1). For VK, the 247 
largest increase was observed for parents who did not know at T1 that the vaccine is recommended for males 248 
aged 9-26 (Figure 2). 249 
Figure 1.  Number of correct answers to each item at Time 2, by their answer at Time 1 for HPV General Knowledge (GK) items. 
 
Note. Data is presented for n=1427 at T1 and n=1427 at T2. For each item, the entire bar represents the number of correct answers at T2. Shading represents the way in which these 
participants remained correct or changed to correct from their initial response at T1. For example, for the item “HPV can be passed on during sexual intercourse”, 1108 correct 
answers at T1 remained correct at T2; 130 ‘Don’t Know’ answers at T1 and 20 incorrect answers at T1 changed to correct at T2.  
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Figure 2. Number of correct answers to each item at Time 2, by their initial answer at Time 1 for HPV Vaccination Knowledge (VK) items. 
 
Note.  
Data is presented for n=1427 at T1 and n=1427 at T2. For each item, the entire bar represents the correct number of answers at T2. Shading represents the way in which these 
participants remained correct or changed to correct from their initial response at T1. For example, for the item “Girls who have had the HPV vaccine do not need a Pap test when 
they are older”, 1060 correct answers at T1 remained correct at T2; 123 ‘Don’t Know’ answers at T1 and 14 incorrect answers at T1 changed to correct at T2
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As a replication analysis, our results support the conclusion that Waller’s HPV general 251 
(GK) and HPV vaccine (VK) knowledge subscales operate as structurally coherent and reliable 252 
measures that can continue to be used in English and now in French. Investigation of the addition 253 
of the 9 new items and the 4 items to the GK and VK subscales respectively, found improved 254 
internal consistency compared to Waller et al.’s (2013), scale. The exception to this was “HPV 255 
usually doesn't need any treatment”, which when removed improved reliability (although not 256 
substantially) and was by far the item which the fewest participants were able to answer 257 
correctly.  258 
Similar to Waller et al., our hypothesis of uni-dimensionality holds for both the GK25 259 
and the VK11 scales. Of note, for the GK25 scale, obtaining three factors with Eigenvalues 260 
greater than one is not of concern because the first factor was typically a very dominant factor 261 
such that subsequent rotated factors often involved cross-loaded items and rarely led to 262 
meaningful factors in item content terms. Item loading results for the GK25 were similar to the 263 
Waller et al.’s results. The item “HPV can cause herpes” and the item “HPV usually doesn't need 264 
any treatment” loaded poorly in both our and Waller’s study.  265 
Interestingly, knowledge of these items was very poor in our Canadian sample which is 266 
in line with other populations (Blake et al., 2015; Bynum et al., 2011; Daley et al., 2010; Gerend 267 
and Shepherd, 2011; Giambi et al., 2014; Holcomb et al., 2004; Kang and Kim, 2011; Marlow et 268 
al., 2013; Mollers et al., 2014; Yacobi et al., 1999). Future consideration should be given to 269 
excluding these items from the GK scales as perhaps they are not necessary to understanding 270 
HPV and may be confusing (e.g., HPV itself does not require any treatment but HPV-associated 271 
diseases do require treatment) and likely unnecessary (e.g., is it relevant to know that HPV does 272 
not cause herpes). Post hoc, we explored the effect of removing these two items from the GK25 273 
scale, and model fit remained largely unchanged and the change in internal consistency was 274 
inconsequential. The decision then to include or exclude these items would thus be left to the 275 
individual researcher, though it is our suggestion to exclude these 2 items, as it make more 276 
substantive sense, leaving a 23-item solution, the GK23. 277 
For the VK11 scale, two items failed to appropriately load: “One of the HPV vaccines 278 
offers protection against genital warts” and “The HPV vaccine only requires one dose”, which 279 
 
 
was similarly found by Waller and colleagues (2013). These items require further attention as 280 
they are conceptually valuable for measuring HPV vaccine knowledge as the protection against 281 
genital warts may be an additional benefit to some individuals to prompt vaccination and dosage 282 
is important as we know that many parents do not complete the full vaccination series. As most 283 
countries are now only using vaccines that prevent both cancers and warts (i.e., 4vHPV and 284 
9vHPV), and as most countries transition to the WHO recommended 2-dose schedule, it may 285 
have confused parents to inter-change HPV vaccine with (‘one of the’) HPV vaccines (plural). 286 
We hypothesize that a slight change in wording/semantics for all VK could potentially improve 287 
model fit, e.g., “The HPV vaccine offers protection against genital warts” and “The HPV vaccine 288 
requires at least 2 doses”. 289 
The mean GK and VK in our sample was poor at both time points i.e. on average, parents 290 
answered around only half the items for both scales correctly, which is consistent with Waller’s 291 
(2013) and most study results  (Davlin et al., 2015; Holcomb et al., 2004; Joseph et al., 2015; 292 
Klug et al., 2008). Item-level analysis showed a similar ranking of knowledge items compared to 293 
Marlow et al.’s study (n =2409 participants living in the UK, US, and Australia, Mage= 41-48, 294 
with 12-14% of them having daughters aged 9-17 (2013). This may suggest a pattern among the 295 
general population where most individuals, regardless of parental status, know about the 296 
association between HPV and cervical cancer and that increasing the number of partners 297 
increases the risk of HPV. In both our and Marlow et al’s sample, most individuals did not know 298 
that “Most sexually active people will get HPV at some point in their lives”. These results 299 
suggest that there may be knowledge gaps that are widespread among different subsamples (e.g., 300 
parents, young adults), and that parents are not acquiring any additional knowledge beyond the 301 
general population. Educational interventions, dispersed in many widespread channels could 302 
target these specific knowledge gaps.  303 
Both GK and VK total scores increased statistically significant over time but the effect 304 
size was small (Cohen’s d <0.3 for the 1427 sample). At Time 1, we provided a brief informative 305 
statement about HPV after the knowledge section, but we estimate that the impact on knowledge 306 
at follow-up was very small, considering the nine months’ time interval between baseline and 307 
follow-up. A closer examination at the item level reveals that correct responses remained 308 
consistent for at least nine months. Moreover, at T2, only a tiny proportion (between 0.8 and 309 
12%) of correct responses can be attributed to a change from incorrect at T1 to correct at T2 and 310 
 
 
a small proportion (10%-51%) can be attributed to a change from ‘Don’t know’ at T1 to correct 311 
at T2. Therefore, we suggest providing both general HPV and HPV vaccine information/facts, 312 
with emphasis on the items that parents do not know, rather than correcting misconceptions. As 313 
an example, specifying the age and gender recommendation in one’s country is advisable. This is 314 
further substantiated by our results which showed an overall pattern across both GK and VK 315 
items where few individuals answered items incorrectly as compared to an often higher 316 
proportion of participants who answered ‘Don’t know’, indicating a lack of HPV knowledge 317 
rather than wrong/misinformation.   318 
Our study is not without limitations. Firstly, our response rate, calculated based on 319 
completion by participants who began the questionnaire (n=5733 at T1 and n=1999 at T2), was 320 
modest (66% at T1 and 80.4% at T2) but superior to other studies (Blake et al., 2015; Gowda et 321 
al., 2012). Secondly, a high attrition (49.9%) can be expected in online surveys, but we believe 322 
that the effect on our results was minimal due to very few significant changes between the 323 
baseline and follow-up sample (see Perez et al., Study Protocol. Under review), and a large 324 
sample at T2. Third, although Leger aimed to maintain a nationally representative panel of 325 
Canadians, there may be differences between panel members and the general Canadian 326 
population (see Perez et al., Study Protocol. Under review). Fourth, we made a few semantic 327 
changes to Waller et al.’s scale, which though minimal, result in an imperfect replication. Lastly, 328 
the internal consistency was lower amongst French speakers compared to English, and the reason 329 
for this requires further exploration. 330 
It remains challenging to compare HPV and HPV vaccine knowledge across studies as 331 
researchers vary extensively in the number of items used (e.g., some use as few as three items 332 
(Allen et al., 2010; Pelucchi et al., 2010), different response options (e.g., multiple choice, true-333 
false, yes/no/not sure, Likert scale, open-ended) and differing content (Davlin et al., 2015; Giede 334 
et al., 2010; Klug et al., 2008). We strongly encourage researchers to utilize the extended GK23 335 
scales to measure HPV knowledge and the VK11 to measure HPV vaccine knowledge, which 336 
could allow for comparisons on the overall knowledge level as well as the item level.  337 
Additionally, beyond English and French, future researchers could translate these scales to other 338 
languages and evaluate the validity among different languages and populations. 339 
 
 
Conclusions  340 
Our extended HPV general knowledge and HPV vaccine knowledge scales are reliable 341 
and unidimensional in both English and French, and capture issues related to both genders. 342 
Interestingly, the added items tended to be least known, which suggests parents may know 343 
specific facts about HPV better (e.g. the link with cervical cancer; that HPV is an STD) than 344 
others (e.g., the link with oral/anal cancers). We suggest educational interventions to inform 345 
about the updated points about HPV and the HPV vaccine that are least known and to focus on 346 
providing information rather than correcting misconceptions. In our opinion, our comprehensive 347 
HPV knowledge scales can significantly contribute to the understanding of how knowledge can 348 
influence vaccine decision-making, and in turn improve, HPV vaccination uptake. 349 
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Supplemental file: Appendix A – English HPV General Knowledge (GK) Items1 
 
                                                          
1 Items 1-16 are from Waller et al.’s scale. Items 17- 25 were added in this study. Items 13 and 21 could ideally be 
removed, leaving a 23-item solution (GK23). We leave this to the discretion of the researchers. Response options 
are: True, False, Don’t know. 
 Please answer the following questions to the best of your ability:  
1. HPV is very rare (F) 
2. HPV always has visible signs or symptoms (F) 
3. HPV can cause cervical cancer (T) 
4. HPV can be transmitted through genital skin-to-skin contact (T) 
5. There are many types of HPV (T) 
6. HPV can cause HIV/AIDS (F) 
7. HPV can be passed on during sexual intercourse (T) 
8. HPV can cause genital warts (T) 
9. Men cannot get HPV (F) 
10. Using condoms reduces the chances of HPV transmission (T) 
11. HPV can be cured with antibiotics (F) 
12. Having many sexual partners increases the risk of getting HPV (T) 
13. HPV usually doesn't need any treatment (T) 
14. Most sexually active people will get HPV at some point in their lives (T) 
15. A person could have HPV for many years without knowing it (T) 
16. Having sex at an early age increases the risk of getting HPV (T) 
17. HPV can cause anal cancer (T) 
18. HPV is a bacterial infection (F) 
19. HPV can be transmitted through oral sex (T) 
20. HPV can cause cancer of the penis (T) 
21. HPV can cause herpes (F) 
22. HPV can be transmitted through anal sex (T) 
23. HPV infections always lead to health problems (F) 
24. HPV can cause oral cancer (T) 
25. A person with no symptoms cannot transmit the HPV infection (F) 
 
 
Supplemental file: Appendix A – English HPV Vaccination Knowledge (VK) Items2 
 
 
 Please answer the following questions to the best of your ability:  
1.  The HPV vaccine3  requires only 1 dose (F)  
2.  The HPV vaccines4 offer protection against all sexually transmitted infections (F) 
3.  The HPV vaccines4 are most effective if given to people who've never had sex (T) 
4.  Someone who has had the HPV vaccine cannot develop cervical cancer (F)  
5.  The HPV vaccines4 offer protection against most cervical cancers (T) 
6.  One of the HPV vaccines4 offers protection against genital warts (T) 
7.  Girls who have had the HPV vaccine do not need a Pap test when they are older (F) 
8.  The HPV vaccine protects you from every type of HPV (F) 
9.  You can cure HPV by getting the HPV vaccine (F) 
10.  
The HPV vaccine is approved and recommended by Health Canada for females aged 9-
45 years (T) 
11.  




                                                          
2 Items 1-7 are from Waller et al.’s scale. Items 8-11 were added in this study. Items 10 and 11 can be adapted to 
each specific country or regions policy/recommendation. Response options are: True, False, Don’t know. 
3 We recommend modifying this item to: The HPV vaccine requires at least 2 doses (T). 
4 We recommend using HPV vaccine (singular) throughout the VK items instead of HPV vaccines (plural) as this 
can be confusing to the reader. For item 6, we recommend the item be asked as follows: The HPV vaccine offers 
protection against genital warts. 
 
 
 Veuillez répondre aux questions suivantes du mieux que vous le pouvez: 
1. Le VPH est très rare (F) 
2. Le VPH présente toujours des signes ou symptômes visibles (F) 
3. Le VPH peut causer le cancer du col de l'utérus (V) 
4. Le VPH peut se transmettre par contact génital peau à peau (V) 
5. Il existe plusieurs types de VPH (V) 
6. Le VPH peut causer le VIH ou le sida (F) 
7. Le VPH peut être transmis au cours de relations sexuelles (V) 
8. Le VPH peut causer des verrues génitales (V) 
9. Les hommes ne peuvent pas contracter le VPH (F) 
10. L'utilisation d'un condom réduit les chances de transmission du VPH (V) 
11. Le VPH peut être guéri avec des antibiotiques (F) 
12. Avoir de nombreux partenaires sexuels augmente les risques de contracter le VPH (V) 
13. Le VPH ne nécessite habituellement pas de traitement (V) 
14. 
La plupart des personnes sexuellement actives contracteront le VPH à un moment ou à un autre 
de leur vie (V) 
15. Une personne pourrait être atteinte du VPH pendant de nombreuses années sans le savoir (V) 
16. Avoir des relations sexuelles à un jeune âge augmente les chances d'attraper le VPH (V) 
17. Le VPH peut causer le cancer de l'anus (V) 
18. Le VPH est une infection bactérienne (F) 
19. Le VPH peut être transmis par sexe oral (V) 
20. Le VPH peut causer le cancer du pénis (V) 
21. Le VPH peut causer l'herpès (F) 
22. Le VPH peut être transmis par sexe anal (V) 
23. Les infections au VPH entraînent toujours des problèmes de santé (F) 
24. Le VPH peut causer le cancer de la bouche (V) 
25. Une personne ne présentant pas de symptômes ne peut pas transmettre le VPH (F) 
 
 
Supplemental File: Appendix B – French HPV General Knowledge Items5 
 




                                                          
5 Items 1-16 are from Waller et al.’s scale. Items 17- 25 were added in this study. Items 13 and 21 could ideally be 
dropped, leaving a 23-item solution (GK23). We leave this to the discretion of the researchers. Response options 
are: Vrai, Faux, Je ne sais pas. 
6Items 1-7 are from Waller et al.’s scale. Items 8-11 were added in this study. Items 10 and 11 can be adapted to 
each specific country or regions policy/recommendation. Response options are: Vrai, Faux, Je ne sais pas.  
7 We recommend modifying this item to: Le vaccin contre le VPH nécessite au moins deux doses (T). 
8We recommend using Le vaccin contre le VPH (singular) throughout the VK items instead of les vaccins contre le 
VPH (plural) as this can be confusing to the reader. For item 6, we recommend the item be asked as follows: Le 
vaccin contre le VPH protège contre les verrues génitales. 
 
 Veuillez répondre aux questions suivantes du mieux que vous le pouvez: 
1.  Le vaccin7 contre le VPH ne nécessite qu'une seule dose (F) 
2.  
Les vaccins8 contre le VPH protègent contre toutes les infections transmises 
sexuellement (F) 
3.  
Les vaccins4 contre le VPH sont les plus efficaces lorsqu'ils sont administrés à des 
personnes n'ayant jamais eu de rapports sexuels (V) 
4.  
Une personne ayant été vaccinée contre le VPH ne peut pas développer le cancer du col 
de l'utérus (F) 
5.  Les vaccins4 contre le VPH protègent contre la plupart des cancers du col de l'utérus (V) 
6.  L'un des vaccins4 contre le VPH protège contre les verrues génitales (V) 
7.  
Les filles ayant été vaccinées contre le VPH n'ont pas besoin de passer de test Pap 
lorsqu'elles sont plus âgées (F) 
8.  Le vaccin contre le VPH vous protège contre tous les types de VPH (F) 
9.  Vous pouvez guérir le VPH en recevant le vaccin contre le VPH (F) 
10.  
Le vaccin contre le VPH est approuvé et recommandé par Santé Canada pour les 
filles/femmes de 9 à 45 ans (V) 
11.  
Le vaccin contre le VPH est approuvé et recommandé par Santé Canada pour les 
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